Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure.
Christophe DesterkeFrank GriscelliJusuf ImeriPaul MarcouxThomas LemonnierTheodoros LatsisAli G TurhanAnnelise Bennaceur-GriscelliPublished in: Stem cells translational medicine (2020)
The use of mesenchymal stem cells (MSC) derived from several sources has been suggested as a major anti-inflammation strategy during the recent outbreak of coronavirus-19 (COVID-19). As the virus enters the target cells through the receptor ACE2, it is important to determine if the MSC population transfused to patients could also be a target for the virus entry. We report here that ACE2 is highly expressed in adult bone marrow, adipose tissue, or umbilical cord-derived MSC. On the other hand, placenta-derived MSC express low levels of ACE2 but only in early passages of cultures. MSC derived from human embryonic stem cell or human induced pluripotent stem cells express also very low levels of ACE2. The transcriptome analysis of the MSCs with lowest expression of ACE2 in fetal-like MSCs is found to be associated in particularly with an anti-inflammatory signature. These results are of major interest for designing future clinical MSC-based stem cell therapies for severe COVID-19 infections.
Keyphrases
- mesenchymal stem cells
- umbilical cord
- cell therapy
- induced pluripotent stem cells
- sars cov
- bone marrow
- stem cells
- angiotensin converting enzyme
- coronavirus disease
- angiotensin ii
- endothelial cells
- adipose tissue
- end stage renal disease
- respiratory syndrome coronavirus
- anti inflammatory
- ejection fraction
- induced apoptosis
- type diabetes
- rna seq
- prognostic factors
- drinking water
- poor prognosis
- pluripotent stem cells
- insulin resistance
- chronic kidney disease
- young adults
- early onset
- long non coding rna
- cell cycle arrest
- current status
- endoplasmic reticulum stress
- cell death
- dna methylation